Yasuyuki Kamada

Dr. Yasuyuki Kamada

Department of Surgery, Kyoto University

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
YYYutaka Yonemura
Yutaka Yonemura
HIHaruaki Ishibashi
Haruaki Ishibashi
AMAkiyoshi Mizumoto
Akiyoshi Mizumoto
GTGorou Tukiyama
Gorou Tukiyama
YLYang Liu
Yang Liu
MMMasahiro Miura
Masahiro Miura
In the present article, we describe the normal structure of the peritoneum and review the mechanisms of peritoneal metastasis (PM) from gastric cancer (GC). The structure of the peritoneum was studied by a double-enzyme staining method using alkaline-phosphatase and 5′-nucreotidase, scanning electron microscopy, and immunohistological methods. The fundamental structure consists of three layers, mesothelial cells and a basement membrane (layer 1), macula cribriformis (MC) (layer 2), and submesothelial connective tissue containing blood vessels and initial lymphatic vessels, attached to holes in the MC (layer 3). Macro molecules and macrophages migrate from mesothelial stomata to the initial lymphatic vessels through holes in the MC. These structures are characteristically found in the diaphragm, omentum, paracolic gutter, pelvic peritoneum, and falciform ligament. The first step of PM is spillage of cancer cells (peritoneal free cancer cells; PFCCs) into the peritoneal cavity from the serosal surface of the primary tumor or cancer cell contamination from lymphatic and blood vessels torn during surgical procedures. After PFCCs adhere to the peritoneal surface, PMs form by three processes, i.e., (1) trans-mesothelial metastasis, (2) trans-lymphatic metastasis, and (3) superficial growing metastasis. Because the intraperitoneal (IP) dose intensity is significantly higher when generated by IP chemotherapy than by systemic chemotherapy, IP chemotherapy has a great role in the treatment of PFCCs, superficial growing metastasis, trans-lymphatic metastasis and in the early stages of trans-mesothelial metastasis. However, an established trans-mesothelial metastasis has its own interstitial tissue and vasculature which generate high interstitial pressure. Accordingly, it is reasonable to treat established trans-mesothelial metastasis by bidirectional chemotherapy from both IP and systemic chemotherapy.

28 January 2021 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
YKYasuyuki Kamada
Yasuyuki Kamada
KHKoya Hida
Koya Hida
HIHaruaki Ishibashi
Haruaki Ishibashi
SSShouzou Sako
Shouzou Sako
AMAkiyoshi Mizumoto
Akiyoshi Mizumoto
YYYutaka Yonemura
Yutaka Yonemura
Background: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) improves survival in selected patients with peritoneal metastasis (PM) from colorectal cancer (CRC). However, little has been reported on characteristics and clinical course of long-term survivors with CRC-PM beyond 5 years. The objective of this study was to identify the clinical and oncological features affecting long-term survival of CRC-PM after comprehensive treatment.Methods: Between January 1990 and April 2015, CRC-PM patients who underwent CRS with or without HIPEC in two Japanese tertiary hospitals were analyzed. Clinicopathological parameters and therapeutic details for long-term survivors (patients surviving ≥ 5 years after CRS) were described and compared with those for non-survivors (patients surviving < 5 years).Results: The study identified 236 patients with CRC-PM who underwent CRS, with a median follow-up period of 2.5 years. Thirty-three patients (14.0%) were considered as long-term survivors. Compared with non-survivors, long-term survivors had a lower median peritoneal cancer index (PCI) [4 (1–27) vs 9 (0–39),p< 0.001]. Complete cytoreduction (CCR-0) was achieved in all long-term survivors, with a significantly higher rate [33/33 (100%) vs 141/203 (69.8%),p< 0.001]. Metachronous onsets of PM were more frequently observed in the long-term survivor group [26/33 (78.8%) vs 103/203 (50.3%),p= 0.018]. Regarding histopathology, long-term survivors more frequently had mucinous adenocarcinoma than non-survivors [8/33 (24.2%) vs 27/203 (13.3%)] and less likely exhibited poorly differentiated or signet ring cell carcinoma [2/33 (6.1%) vs 48/203 (23.7%)] (p< 0.001).Conclusions: One in seven patients with CRC-PM achieved the long-term milestone after CRS. A long-term survival was associated with the presence of low PCI, CCR-0, metachronous onset, and mucinous histology.

13 June 2021 in Cancers
Verified
Journal Article
Open access
PDF file
YKYasuyuki Kamada
Yasuyuki Kamada
KHKoy Hid
Koy Hid
YYYutaka Yonemura
Yutaka Yonemura
PSPaul Sugarbaker
Paul Sugarbaker
SGShadin Ghabra
Shadin Ghabra
OGOlivier Glehen
Olivier Glehen
Background: We conducted this study to review the patient characteristics associated with long-term survival in patients with peritoneal metastases from colorectal cancer who underwent cytoreductive surgery (CRS). Methods: We retrospectively investigated patients with peritoneal metastases from CRC treated with curative intent surgery with or without hyperthermic intraperitoneal chemotherapy at 13 institutions worldwide between January 1985 and April 2015 and survived longer than five years after the first CRS for peritoneal metastases. Clinical and oncological features and therapeutic parameters were described and analyzed. Results: Two hundred six long-term survivors were available for study. The median peritoneal cancer index (PCI) of this cohort was 4 (interquartile range (IQR), 2–7), and the median score of the small bowel regions of the PCI (SB-PCI) was 0 (IQR, 0–2). Complete cytoreduction (CC-0) was achieved in 180 (87.4%) patients. Recurrence was observed in 122 (59.2%) patients at a median of 1.8 (IQR, 1.2–2.6) years. Conclusions: While most long-term survivors showed low PCI/SB-PCI and CCR-0, some had characteristics considered associated with poor prognosis. Curative intent treatments may be considered in well-informed and fit patients showing negative factors affecting survival outcome.

5 November 2023 in Surgical Oncology
Verified
Journal Article
Closed access
YKYasuyuki Kamada
Yasuyuki Kamada
KHKoy Hid
Koy Hid
YYYutaka Yonemura
Yutaka Yonemura
ANAkiyoshi Nakakura
Akiyoshi Nakakura
TKToshiyuki Kitai
Toshiyuki Kitai
KOKazutaka Obama
Kazutaka Obama

18 November 2020 in Research Square
Verified
Preprint
Open access
PDF file
YKYasuyuki Kamada
Yasuyuki Kamada
KHKoya Hida
Koya Hida
HIHaruaki Ishibashi
Haruaki Ishibashi
SSShouzou Sako
Shouzou Sako
AMAkiyoshi Mizumoto
Akiyoshi Mizumoto
YYYutaka Yonemura
Yutaka Yonemura
BackgroundCytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) improves survival in selected patients with peritoneal metastasis (PM) from colorectal cancer (CRC). However, little has been reported on characteristics and clinical course of long-term survivors with CRC-PM beyond 5 years. The objective of this study was to describe the clinical and oncological features affecting long-term survival of CRC-PM after comprehensive treatment.MethodsBetween January 1990 and April 2015, CRC-PM patients who underwent CRS with or without HIPEC in two Japanese tertiary hospitals and who survived longer than 5 years after the first CRS for PM were retrospectively investigated. Clinicopathological parameters and therapeutic details involved in long-term survival were reviewed. Patients were defined as cured if the recurrence-free interval was > 5 years after the last operation for metastases.ResultsThirty-three patients with a median peritoneal cancer index (PCI) of 4 (range, 1–27) were included. Complete cytoreduction was achieved in all 33 patients, and none had a rectal primary. Recurrence was observed in 19 patients (57.6%) at a median of 2.6 (range, 0.7–7.4) years. Sixteen patients (48.5%) were considered cured, of whom two never developed re-recurrence after the second surgery. The median PCI of cured group was 2 (range, 1–8).ConclusionsLong-term survival and cure were obtained after CRS in selected patients with CRC-PM. Low PCI, complete cytoreduction, and non-rectal primary are associated with long-term survival and cure in PM from CRC.